Salmaso Stefano, Bersani Sara, Semenzato Alessandra, Caliceti Paolo
Department of Pharmaceutical Sciences, University of Padua, Via F Marzolo, 5-35131 Padua, Italy.
J Nanosci Nanotechnol. 2006 Sep-Oct;6(9-10):2736-53. doi: 10.1166/jnn.2006.456.
The growth rate for biotech drugs, namely proteins, peptides, and oligonucleotides, is dictated by the parallel progresses in biotechnology and nanotechnology. Actually, biotechnology techniques have expanded enormously the arsenal of therapeutically useful peptides and proteins making these products of primary interest for future pharmaceutical market. Nevertheless, the exploitation of protein and peptide drugs is strictly related to the development of innovative delivery systems which should provide for controlled, prolonged, or targeted delivery, improved stability during storage and delivery, reduced adverse effects, increased bioavailability, improved patient compliance and allow for administration through the desired route and cope with cost-containment therapeutic protocols. Colloidal formulations ideally possess the physicochemical and biopharmaceutical requisites for protein delivery. Pharmaceutical nanotechnology is a tool of techniques applied to design, develop and produce these systems. It involves the investigation of innovative materials and production procedures for preparation of a variety of nanosized dosage forms, which range from solid nanoparticles to soluble bioconjugates. The research and development of innovative tailor made protein delivery systems, which must be designed according to the drug candidate pharmacological and physicochemical properties, is one of the primary aim of modern pharmaceutical technology. Therefore, as an unmet need exists for technologies that combine innovative drug delivery solutions, a close un-prejudicial interaction between academic and industrial researchers as well as business thought leaders is required.
生物技术药物（即蛋白质、肽和寡核苷酸）的增长率取决于生物技术和纳米技术的同步发展。实际上，生物技术技术极大地扩充了具有治疗作用的肽和蛋白质的种类，使这些产品成为未来医药市场的主要关注点。然而，蛋白质和肽类药物的开发与创新给药系统的发展密切相关，这种给药系统应能实现可控、长效或靶向给药，在储存和给药过程中提高稳定性，减少不良反应，提高生物利用度，改善患者顺应性，并允许通过期望的途径给药，同时符合成本控制治疗方案。胶体制剂理想地具备蛋白质给药所需的物理化学和生物药学条件。药物纳米技术是用于设计、开发和生产这些系统的一系列技术手段。它涉及研究创新材料和生产工艺，以制备从固体纳米颗粒到可溶性生物共轭物等各种纳米尺寸剂型。根据候选药物的药理和物理化学性质设计创新的定制蛋白质给药系统，是现代制药技术的主要目标之一。因此，由于结合创新药物递送解决方案的技术仍存在未满足的需求，学术研究人员、产业研究人员以及商业思想领袖之间需要进行密切且无偏见的互动。
